<p><b>OBJECTIVE</b>To study the changes of
adenosine diphosphate (
ADP )-induced
platelet aggregation rate, and evaluate the effects of Maixuekang
Capsule (, MKC) on
platelet aggregation rate and long-term
prognosis of
patients with
acute coronary syndrome after
percutaneous coronary intervention (PCI).</p><p><b>
METHODS </b>A total of 236
patients with
acute coronary syndrome ,
who received successful PCI, were randomly assigned to a trial group (116 cases) and a
control group (120 cases) according to random numbers;
treatment allocation occurred when the participants met the inclusion criteria and signed the
informed consent forms . In the trial group, the
patients were treated with MKC combined with routine medication, and in the
control group the
patients were treated with routine medication. The
therapeutic course for the two groups was 12 months and the follow-up was 12 months. The levels of
ADP -induced
platelet aggregation rate and
serum high-sensitive
C-reactive protein (
hs-CRP ) were determined before PCI, 12 h and 30 days after PCI. In the meantime, the
incidence of cardio-/cerebrovascular events was recorded during the 12-month follow-up.</p><p><b>RESULTS</b>Compared with before PCI, the levels of
ADP -induced
platelet aggregation rate and
serum hs-CRP were significantly higher at 12 h after PCI (P<0.05). They were significantly reduced after 30-day-
treatment of MKC, showing statistical differences when compared with those in the
control group (P<0.05). During the 12-month follow-up, the
incidence of cardio-/cerebrovascular events was significantly lower in the trial group than in the
control group (6.9% vs. 12.5%, P<0.01).</p><p><b>CONCLUSIONS</b>
ADP -induced
platelet aggregation function was significantly elevated after PCI. MKC improved the
prognosis of
patients with
acute coronary syndrome , possibly through inhibiting the
platelet aggregation , fighting against
inflammation , and protecting the vascular endothelial function.</p>